Nautilus Biotechnology Reveals New Insights into Tau Proteoforms with Iterative Mapping Technology

Nautilus Biotechnology, Inc., a pioneer in single-molecule proteome analysis, has unveiled groundbreaking research published in Nature Methods, detailing the company's Iterative Mapping technology. The study, titled "Large-scale single-molecule analysis of tau proteoforms," provides new insights into the diverse forms of the tau protein and their roles in disease.

The research, led by Parag Mallick, Ph.D., Co-Founder and Chief Scientist of Nautilus, and his team, quantified 130 distinct tau proteoform groups across various model systems, including cell-derived models, organoids, mouse brains, and human brain samples. This unprecedented level of detail was made possible by the Nautilus Tau Proteoforms Assay, which employs 12 site-specific antibodies and Iterative Mapping to resolve full-length tau molecules with single-molecule resolution.

The findings reveal that specific combinations of disease-associated modifications occur in a non-random sequence, a discovery that could have significant implications for developing new diagnostics and therapeutics. According to Dr. Mallick, "Until now, we haven't had the ability to quantify proteoforms and connect them to specific functions at scale. Iterative Mapping changes that. This study shows, for the first time, that tau proteoforms are non-random and closely tied to disease biology."

Dr. Taylor Bertucci, Principal Investigator at the Neural Stem Cell Institute and a collaborator on the study, noted, "What surprised us most is how differently tau behaves across the model systems our field relies on every day. This has immediate consequences for how biomarker studies are designed and how drug programs choose their models."

The study's results highlight the potential of Iterative Mapping to provide novel insights into disease mechanisms. For instance, the assay quantified proteoforms at 0.1% of a sample, with a median coefficient of variation below 5.5%, demonstrating precision and sensitivity. The team observed that specific combinations of tau modifications co-occurred more often than would be expected by chance, indicating that tau is modified in a consistent, ordered sequence. This discovery could lead to the identification of new biomarkers and drug targets.

The findings also suggest that certain proteoforms may serve as powerful indicators of disease progression. For example, the patient with the most severe pathology carried the most heavily phosphorylated tau, including 1N3R tau quadruply phosphorylated at pT181-pT217-pT231-pS396. Such detailed insights could accelerate the development of earlier diagnostics and more precise therapies for Alzheimer's disease and related tauopathies.

Nautilus plans to apply Iterative Mapping to other disease targets, including α-synuclein in Parkinson's disease and AKT1, the company's first oncology proteoform assay, which is expected to enter the Iterative Mapping Early Access Program (EAP) in late 2026. Two additional oncology targets have cleared Nautilus' development criteria, indicating that the company aims to develop approximately 20 proteoform assays by mid-2028.

The Nautilus Voyager™ Platform, which employs Iterative Mapping, is designed to enable rapid measurement of intact, single-molecule proteins and proteoforms in a single, sample-to-answer workflow. The platform's flow cells can accommodate up to 10 billion intact protein molecules, providing a wide dynamic range for measurement. Machine learning algorithms convert probe-binding patterns into confident protein and proteoform identifications, producing structured, reproducible data.

Nautilus Biotechnology, Inc., headquartered in Seattle, Washington, and with its research and development headquarters in San Carlos, California, continues to advance its platform technology to democratize access to the proteome and enable fundamental advancements across human health and medicine.